# Combination Ranibizumab and Bromfenac for Neovascular Age-related Macular Degeneration

> **NCT00805233** · PHASE2 · COMPLETED · sponsor: **Oregon Health and Science University** · enrollment: 30 (estimated)

## Conditions studied

- Age-Related Macular Degeneration

## Interventions

- **DRUG:** combination ranibizumab + bromfenac
- **DRUG:** ranibizumab injection alone

## Key facts

- **NCT ID:** NCT00805233
- **Lead sponsor:** Oregon Health and Science University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2011-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00805233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00805233, "Combination Ranibizumab and Bromfenac for Neovascular Age-related Macular Degeneration". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00805233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*